|Articles|April 15, 2002
- BioPharm International-04-01-2002
- Volume 15
- Issue 4
Beyond QSIT
Author(s)Joseph F. Noferi, Esq., Daniel E. Worden
by Joseph F. Noferi, Pharmacia GS API Biopharma and Daniel E. Worden If a process is out of control, an FDA inspector will find it, eventually. Companies that emerge as winners will be those that embrace compliance as a core business practice. Systems models provide strategic competitive advantage.
Advertisement
Articles in this issue
over 23 years ago
Analytical Advances: Paperless or Less Paper?over 23 years ago
Determining Protein Concentration, Part 1: Methodologyover 23 years ago
Guest Editorial: The Protein Production Challengeover 23 years ago
Business Matters: Personalized Medicine or Blockbusterology?over 23 years ago
Advances in Amino Acid AnalysisNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
2
Charles River Incubator Cohort to Accelerate CGT Development
3
FAQ: Shifts in FDA Regulations and Strategies in 2025
4
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
5
